Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure

Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure. GLUCOSUR-IC Study

Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and hemodynamic profile in patients with DM2 and heart failure.

Inclusion Criteria:

• Type 2 Diabetes
• HbA1c> 6.5%
• Estimated GF> 45 ml / min
• BMI: ≥25 Kg / m2
• Stable pharmacological treatment of Heart Failure in the last 3 months

Exclusion Criteria:

• Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive)
• DM2 with C-peptide <1 ng / mL
• GEF <45 ml / min
• Recurrent urinary tract infections